|
1
|
Brastianos PK, Curry WT and Oh KS:
Clinical discussion and review of the management of brain
metastases. J Natl Compr Canc Netw. 11:1153–1164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kyritsis AP, Markoula S and Levin VA: A
systematic approach to the management of patients with brain
metastases of known or unknown primary site. Cancer Chemother
Pharmacol. 69:1–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brastianos PK, Carter SL, Santagata S,
Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS,
Horowitz PM, Cibulskis K, et al: Genomic characterization of brain
metastases reveals branched evolution and potential therapeutic
targets. Cancer Discov. 5:1164–1177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang H, Ou Q, Li D, Qin T, Bao H, Hou X,
Wang K, Wang F, Deng Q, Liang J, et al: Genes associated with
increased brain metastasis risk in non-small cell lung cancer:
Comprehensive genomic profiling of 61 resected brain metastases
versus primary non-small cell lung cancer (Guangdong Association
Study of Thoracic Oncology 1036). Cancer. 125:3535–3544. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson GD, Johnson MD, Ahmed S, Cardenas
PY, Grills IS and Thibodeau BJ: Targeted DNA sequencing of
non-small cell lung cancer identifies mutations associated with
brain metastases. Oncotarget. 9:25957–25970. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun J, Wang C, Zhang Y, Xu L, Fang W, Zhu
Y, Zheng Y, Chen X, Xie X, Hu X, et al: Genomic signatures reveal
DNA damage response deficiency in colorectal cancer brain
metastases. Nat Commun. 10:31902019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steeg PS, Camphausen KA and Smith QR:
Brain metastases as preventive and therapeutic targets. Nat Rev
Cancer. 11:352–363. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H and Durbin R: Fast and accurate
long-read alignment with Burrows-Wheeler transform. Bioinformatics.
26:589–595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome
Project Data Processing Subgroup, : The sequence alignment/map
format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
1000 Genomes Project Consortium, .
Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker
RE, Kang HM, Marth GT and McVean GA: An integrated map of genetic
variation from 1,092 human genomes. Nature. 491:562012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lek M, Karczewski KJ, Minikel EV, Samocha
KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ,
Cummings BB, et al: Analysis of protein-coding genetic variation in
60,706 humans. Nature. 536:285–291. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet.
48:607–616. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodriguez A, Gallon J, Akhoundova D,
Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V,
Tomlins S, et al: The genomic landscape of prostate cancer brain
metastases. BioRxiv; 2020
|
|
16
|
Patel DS, Misenko SM, Her J and Bunting
SF: BLM helicase regulates DNA repair by counteracting RAD51
loading at DNA double-strand break sites. J Cell Biol.
216:3521–3534. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salvador Moreno N, Liu J, Haas KM, Parker
LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C,
Robinson PJ, et al: The nuclear structural protein NuMA is a
negative regulator of 53BP1 in DNA double-strand break repair.
Nucleic Acids Res. 47:2703–2715. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jordan EJ, Kim HR, Arcila ME, Barron D,
Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, et al:
Prospective comprehensive molecular characterization of lung
adenocarcinomas for efficient patient matching to approved and
emerging therapies. Cancer Discov. 7:596–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woditschka S, Evans L, Duchnowska R, Reed
LT, Palmieri D, Qian Y, Badve S, Sledge G Jr, Gril B, Aladjem MI,
et al: DNA double-strand break repair genes and oxidative damage in
brain metastasis of breast cancer. J Natl Cancer Inst.
106:dju1452014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diossy M, Reiniger L, Sztupinszki Z,
Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC,
Tóth E, et al: Breast cancer brain metastases show increased levels
of genomic aberration-based homologous recombination deficiency
scores relative to their corresponding primary tumors. Ann Oncol.
29:1948–1954. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han CH and Brastianos PK: Genetic
characterization of brain metastases in the era of targeted
therapy. Front Oncol. 7:2302017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei Q, Ye Z, Zhong X, Li L, Wang C, Myers
RE, Palazzo JP, Fortuna D, Yan A, Waldman SA, et al: Multiregion
whole-exome sequencing of matched primary and metastatic tumors
revealed genomic heterogeneity and suggested polyclonal seeding in
colorectal cancer metastasis. Ann Oncol. 28:2135–2141. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cooper CS, Eeles R, Wedge DC, Van Loo P,
Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N,
et al: Analysis of the genetic phylogeny of multifocal prostate
cancer identifies multiple independent clonal expansions in
neoplastic and morphologically normal prostate tissue. Nat Genet.
47:367–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen G, Chakravarti N, Aardalen K, Lazar
AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal
YN, et al: Molecular profiling of patient-matched brain and
extracranial melanoma metastases implicates the PI3K pathway as a
therapeutic target. Clin Cancer Res. 20:5537–5546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niessner H, Schmitz J, Tabatabai G, Schmid
AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C,
Schittek B, et al: PI3K pathway inhibition achieves potent
antitumor activity in melanoma brain metastases in vitro and in
vivo. Clin Cancer Res. 22:5818–5828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tie J, Lipton L, Desai J, Gibbs P,
Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans
PM, et al: KRAS mutation is associated with lung metastasis in
patients with curatively resected colorectal cancer. Clin Cancer
Res. 17:1122–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liao L, Ji X, Ge M, Zhan Q, Huang R, Liang
X and Zhou X: Characterization of genetic alterations in brain
metastases from non-small cell lung cancer. FEBS Open Bio.
8:1544–1552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Petitjean A, Achatz MI, Borresen-Dale AL,
Hainaut P and Olivier M: TP53 mutations in human cancers:
Functional selection and impact on cancer prognosis and outcomes.
Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mukhopadhyay UK, Eves R, Jia L, Mooney P
and Mak AS: p53 suppresses Src-induced podosome and rosette
formation and cellular invasiveness through the upregulation of
caldesmon. Mol Cell Biol. 29:3088–3098. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Muller PA, Vousden KH and Norman JC: p53
and its mutants in tumor cell migration and invasion. J Cell Biol.
192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lo Nigro C, Vivenza D, Monteverde M,
Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR,
Syed N, et al: High frequency of complex TP53 mutations in CNS
metastases from breast cancer. Br J Cancer. 106:397–404. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JY, Park K, Lim SH, Kim HS, Yoo KH,
Jung KS, Song HN, Hong M, Do IG, Ahn T, et al: Mutational profiling
of brain metastasis from breast cancer: Matched pair analysis of
targeted sequencing between brain metastasis and primary breast
cancer. Oncotarget. 6:43731–43742. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P,
Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of
p53 transcription-factor binding sites in the human genome. Cell.
124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Endo A, Moyori A, Kobayashi A and Wong RW:
Nuclear mitotic apparatus protein, NuMA, modulates p53-mediated
transcription in cancer cells. Cell Death Dis. 4:e7132013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ohata H, Miyazaki M, Otomo R,
Matsushima-Hibiya Y, Otsubo C, Nagase T, Arakawa H, Yokota J,
Nakagama H, Taya Y and Enari M: NuMA is required for the selective
induction of p53 target genes. Mol Cell Biol. 33:2447–2457. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sebestyén E, Singh B, Miñana B, Mateo F,
Pujana MA, Valcárcel J and Eyras E: Large-scale analysis of genome
and transcriptome alterations in multiple tumors unveils novel
cancer-relevant splicing networks. Genome Res. 26:732–744. 2016.
View Article : Google Scholar : PubMed/NCBI
|
